Last updated on February 2018

A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)


Brief description of study

This disease registry is a prospective, multicenter non-interventional study designed to observe anti-cancer treatment regimens and clinical outcomes in participants with HER2-positive unresectable LA/mBC. Diagnosis of unresectable LA or mBC can be up to 6 months old prior to registry enrollment.

Clinical Study Identifier: NCT02913456

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: MO39146 ...

Hospital Garcia de Orta; Servico de Oncologia Medica
Almada, Portugal
0.24miles
  Connect »

Reference Study ID Number: MO39146 ...

Hospital Santo Antonio dos Capuchos;Servico de Oncologia Medica
Lisboa, Portugal
3.73miles
  Connect »

Reference Study ID Number: MO39146 ...

Hospital de Santa Maria; Servico de Oncologia Medica
Lisboa, Portugal
3.75miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.